Advertisement

ß-Blocker in der stabilen und instabilen koronaren Herzerkrankung

  • R. H. Strasser

Zusammenfassung

Die stabile und instabile Angina pectoris sind zwei Entitäten der koronaren Herzerkrankung, die mit ihren klinisch zu differenzierenden Charakteristika bei demselben Patienten in Sequenz auftreten können [1]. Die Unterscheidungsmerkmale, insbesondere hinsichtlich der Aktualität und Instability, besonders aber auch hinsichtlich ihrer unterschiedlichen Prognose, bestimmen die Aggressivität der Behandlungsstrategien. Die Prognose der instabilen Angina ist deutlich schlechter als die Prognose der stabilen Angina und wird wesentlich bestimmt durch Parameter, die bereits auf den ischämischen Untergang von myokardialem Gewebe hinweisen. Dazu zählen beispielsweise EKG-Veränderungen und die Freisetzung von kardialem Troponin I und Troponin T [2-5].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Rizik DG, Healy S, Margulis A et al. (1995) A new clinical classification for hospital prognosis of unstable angina pectoris. Am J Cardiol 75: 993–997.PubMedCrossRefGoogle Scholar
  2. 2.
    Renard M (1996) Bedside determination of cardiac troponin T. Circulation 94: 2313–2314.PubMedGoogle Scholar
  3. 3.
    Ohman EM, Armstrong PW, Christenson RH et al. (1996) Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 335: 1333–1341.PubMedCrossRefGoogle Scholar
  4. 4.
    Antman EM, Tanasijevic MJ, Thompson B et al. (1996) Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 335: 1342–1349.PubMedCrossRefGoogle Scholar
  5. 5.
    Van de Werf F (1996) Cardiac troponins in acute coronary syndromes. N Engl J Med 335: 1388–1389.PubMedCrossRefGoogle Scholar
  6. 6.
    Fuster V (1994) Lewis A. Conner memorial lecture: Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 90: 2126–2146.Google Scholar
  7. 7.
    Fuster V, Badimon J J, Badimon L (1992) Clinical-pathological correlations of coronary disease progression and regression. Circulation 86: III 1–11.Google Scholar
  8. 8.
    Hansson L (1991) Review of state-of-the-art beta-blocker therapy. Am J Cardiol 67: 43B–46B.PubMedCrossRefGoogle Scholar
  9. 9.
    Herlitz J, Elmfeldt D, Holmberg S et al. (1984) Goteborg Metoprolol Trial: mortality and causes of death. Am J Cardiol 53: 9D–14D.PubMedCrossRefGoogle Scholar
  10. 10.
    Hjalmarson Å, Olsson G (1991) Myocardial infarction. Effects of beta-blockade. Circulation 84: VI101–107.Google Scholar
  11. 11.
    Kendall MJ, Lynch KP, Hjalmarson Å, Kjekshus J (1995) Beta-blockers and sudden cardiac death. Ann Intern Med 123: 358–367.PubMedGoogle Scholar
  12. 12.
    Schömig A, Dart AM, Dietz R, Mayer E, Kübler W (1984) Release of endogenous catecholami-nes in the ischemic myocardium of the rat. Part A: locally mediated release. Circ Res 55: 689–701.Google Scholar
  13. 13.
    Ungerer M, Chlistalla A, Richardt G (1996) Upregulation of cardiac uptake 1 carrier in ische-mic and nonischemic rat heart. Circ Res 78: 1037–1043.PubMedGoogle Scholar
  14. 14.
    Strasser RH, Krimmer J, Braun-Dullaeus R, Marquetant R, Kübler W (1990) Dual sensitization of the adrenergic system in early myocardial ischemia: Independent regulation of the β-adrenergic receptors and the adenylyl cyclase. J Mol Cell Cardiol 22: 1405–1423.PubMedCrossRefGoogle Scholar
  15. 15.
    Strasser RH, Benovic JL, Caron MG, Lefkowitz RJ (1987) Desensitization of the β-adrenergic coupled adenylate cyclase: The β-adrenergic receptor kinase phosphorylates agonist-occupied cyclase-coupled receptors. Cell Biol 6: 95–115.Google Scholar
  16. 16.
    Lefkowitz RJ, Cotecchia S, Kjelsberg MA, Pitcher J, Koch WJ, Inglese J, Caron MG (1993) Adrenergic receptors: Recent insights into their mechanism of activation and desensitization. Adv Second Messenger Phosphoprotein Res 29: 1–9.Google Scholar
  17. 17.
    Strasser RH, Krimmer J, Marquetant R (1988) Regulation of P-adrenergic receptors: Impaired desensitization in myocardial ischemia. J Cardiovasc Pharmacol 12: S15–S24.PubMedCrossRefGoogle Scholar
  18. 18.
    Ihl-Vahl R, Bremerich J, Marquetant R, Strasser RH (1995) Regulation of β-adrenergic recep-tors in myocardial ischemia: Subtype-selective increase of mRNA specific for β1-adrenergic receptors. J Mol Cell Cardiol 27: 437–452.PubMedCrossRefGoogle Scholar
  19. 19.
    Kübler W, Strasser RH (1994) Signal transduction in myocardial ischemia. Eur Heart J 15: 437–445.PubMedGoogle Scholar
  20. 20.
    Strasser RH, Marquetant R (1991) Sensitization of the β-adrenergic system in acute myocar-dial ischemia by a protein kinase C-dependent mechanism. Eur Heart J 12: 48–53.PubMedGoogle Scholar
  21. 21.
    First International Study of Infarct Survival Collaborative Group (1986) Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2: 57–66.Google Scholar
  22. 22.
    MIAMI Trial Research Group (1985) Metoprolol in acute myocardial infarction (MIAMI): A randomized placebo-controlled trial. Eur Heart J 6: 199–226.Google Scholar
  23. 23.
    Moss AJ, Benhorin J (1990) Prognosis and management after a first myocardial infarction. N Engl J Med 322: 743–753.PubMedCrossRefGoogle Scholar
  24. 24.
    Levy S (1990) Secondary prevention after myocardial infarction: in favor of beta-blockers. J Cardiovasc Pharmacol 16, Suppl 6: S50–4.PubMedGoogle Scholar
  25. 25.
    Viscoli CM, Horwitz RI, Singer BH (1993) Beta-Blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness. Ann Intern Med 118: 99–105.PubMedGoogle Scholar
  26. 26.
    Yusuf S, Sleight P, Ross P, Ramsdale D, Gray R, Bennett D, Bray C (1983) Reduction in infarct size, arrhythmias and chest pain by early intravenous β-blockade in suspected acute myocar-dial infarction. Circulation 67 (Suppl): I–32–I–41.Google Scholar
  27. 27.
    Yusuf S, Lessem J, Jha P, Lonn E (1993) Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens 11: S61–73.CrossRefGoogle Scholar
  28. 28.
    Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) P-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335–371.PubMedCrossRefGoogle Scholar
  29. 29.
    Detry JM (1993) Clinical features of an anti-anginal drug in angina pectoris. Eur Heart J 14 Suppl G: 18–24.PubMedCrossRefGoogle Scholar
  30. 30.
    Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC (1992) Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327: 248–254.PubMedCrossRefGoogle Scholar
  31. 31.
    Olsson G, Wikstrand J, Warnold I et al. (1992) Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 13: 28–32.PubMedGoogle Scholar
  32. 32.
    Parker JD, Testa MA, Jimenez AH, Tofler GH, Muller JE, Parker JO, Stone PH (1994) Morning increase in ambulatory ischemia in patients with stable coronary artery disease. Importance of physical activity and increased cardiac demand. Circulation 89: 604–614.Google Scholar
  33. 33.
    Deedwania PC, Carbajal EV (1990) Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation 81: 748–756.PubMedCrossRefGoogle Scholar
  34. 34.
    Portegies MCM, Sijbring P, Gobel EJAM, Viersma JW, Lie KI (1994) Efficacy of metoprolol and diltiazem in treating silent myocardial ischemia. Am J Cardiol 74: 1095–1098.PubMedCrossRefGoogle Scholar
  35. 35.
    Beta-Blocker Heart Attack Trail Research Group (1982) A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247: 1707–1714.Google Scholar
  36. 36.
    Fowler MB (1993) Controlled trials with β-blockers in heart failure: metoprolol as the proto¬type. Am J Cardiol 71: 45C–53C.PubMedCrossRefGoogle Scholar
  37. 37.
    Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effects of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1349–1355.PubMedCrossRefGoogle Scholar
  38. 38.
    Hjalmarson Å, Waagstein F (1991) New therapeutic strategies in chronic heart failure: chal-lenge of long-term β-blockade, Eur Heart J 12, Suppl F: 63–69.PubMedGoogle Scholar
  39. 39.
    Ryan TJ, Anderson JL, Antman EM et al. (1996) ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary - A report of the American College of Cardiology American Heart Association Task Force on practice guidelines (Com-mittee on management of acute myocardial infarction). Circulation 94: 2341–2350.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • R. H. Strasser

There are no affiliations available

Personalised recommendations